Skip to NavigationSkip to content

Drug therapy

Pfizer supressed research suggesting arthritis drug Enbrel reduced risk of Alzheimer's by 64%

Pfizer supressed data suggesting that their drug Enbrel reduced the risk of patients developing Alzheimer’s disease by 64%.

In 2015, researchers at Pfizer found that the powerful anti-inflammatory Enbrel – which is approved for the treatment of rheumatoid arthritis in the United States – reduced the risk of patients developing Alzheimer’s disease.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches